Retatrutide Research: Phase 2, TRIUMPH Phase 3, and the Clinical Evidence — Clinic Retatrutide
What the science covers — briefly
Retatrutide's published clinical record spans a Phase 1b pharmacokinetics study (2022), two Phase 2 trials in obesity and type 2 diabetes (2023), a Phase 2a liver-fat substudy (2024), structural biology at atomic resolution (2024), and Phase 3 TRIUMPH-1 topline results (2025). This page organizes those findings by trial and mechanism.
Three receptors are activated at once: GLP-1R (appetite suppression and glucose-dependent insulin secretion), GIPR (incretin potentiation), and GCGR (thermogenesis and hepatic fat oxidation). The glucagon receptor arm is what distinguishes retatrutide from dual agonists and is thought to drive the additional weight loss observed in indirect comparisons.
Every quantitative claim on this page is tied to a specific trial and a citation number. The goal is to make the published record readable — not to interpret it as medical guidance.
Retatrutide's published clinical record spans Phase 2 trials in obesity and type 2 diabetes (2023), a Phase 2a liver disease study (2024), Phase 3 TRIUMPH-1 and TRIUMPH-4 topline results (2025), and a structural biology study resolving triple-receptor binding at near-atomic resolution (2024). This page summarizes the key findings, organized by trial. Every quantitative claim is cited.
Retatrutide Mechanism of Action: Triple Agonist Pathway
Retatrutide simultaneously activates three hormone receptors: GLP-1R (satiety and glucose-dependent insulin secretion), GIPR (incretin potentiation and fat metabolism), and GCGR (thermogenesis, hepatic fatty acid oxidation, and hepatic glucose output). The combination produces additive and complementary metabolic effects that no single-receptor or dual-receptor agent achieves alone.
Receptor potency profile (relative to endogenous ligands): retatrutide is 8.9 times more potent at GIPR than endogenous GIP; 0.4 times as potent at GLP-1R as endogenous GLP-1; and 0.3 times as potent at GCGR as endogenous glucagon. The moderate GCGR agonism, balanced by simultaneous GLP-1R and GIPR activation, prevents the hyperglycemia that glucagon monotherapy would cause.
Cryo-EM structures resolved in 2024 (Li et al., Cell Discovery) captured retatrutide simultaneously engaging all three receptors at near-atomic resolution: GLP-1R-Gs complex at 2.68 Å, GIPR-Gs at 3.26 Å, GCGR-Gs at 2.84 Å. The peptide forms a single continuous helix penetrating each receptor's transmembrane domain core. Receptor-specific binding is mediated by differing ECL1 conformations: GLP-1R and GCGR form short alpha-helices; GIPR ECL1 adopts an unwound loop due to three proline residues [4].
The Aib2 N-terminal substitution confers DPP-4 resistance, extending plasma half-life to approximately 6 days and enabling once-weekly subcutaneous dosing [19]. A C20 fatty diacid moiety provides albumin binding to further extend circulatory residence.
Is Retatrutide a GLP-3 Agonist?
Retatrutide is sometimes informally called a 'GLP-3' — shorthand for triple agonist. This is not a formal pharmacological classification. The receptor nomenclature 'GLP-3' does not exist in approved pharmacology; 'GLP-1' and 'GLP-2' refer to specific incretin hormones (GLP-2 acts primarily on intestinal epithelium and is unrelated to retatrutide's mechanism).
Retatrutide's precise formal classification is a GLP-1/GIP/glucagon receptor co-agonist. The 'GLP-3' colloquialism is increasingly common in patient forums and lay-press coverage; it is used as shorthand for 'triple agonist,' not as a reference to any specific hormone or receptor family.
How Does Retatrutide Work?
GLP-1R activation: suppresses glucagon, slows gastric emptying, enhances glucose-dependent insulin secretion, and reduces appetite via hypothalamic and brainstem signaling. This is the mechanism shared with semaglutide and tirzepatide.
GIPR activation: potentiates insulin secretion in a glucose-dependent manner, modulates adipose tissue lipid metabolism, and complements GLP-1R effects on satiety. Tirzepatide also activates GIPR, making it a dual agonist.
GCGR activation: this is the pathway that distinguishes retatrutide. Glucagon receptor agonism increases hepatic glucose output under normal conditions — but when co-activated with GLP-1R, the hyperglycemia risk is offset. What remains are the beneficial effects: enhanced energy expenditure via brown adipose tissue thermogenesis (cAMP/PKA-mediated UCP-1 activation), stimulated hepatic fatty acid oxidation, increased lipolysis, and elevated resting metabolic rate [13].
Additionally, class-level GLP-1R agonism modulates mesolimbic dopamine signaling in the VTA and nucleus accumbens, reducing reward-circuit-driven hyperphagia — an effect studied in rodent models and early-phase human clinical trials [15].
Phase 2 Obesity Trial: Jastreboff 2023 (NEJM)
The pivotal Phase 2 obesity trial (NCT04881760; Jastreboff AM et al., NEJM 2023) enrolled 338 adults with BMI 30 or greater (or 27 or greater with a comorbidity) without type 2 diabetes. Participants were randomized to retatrutide 1 mg, 4 mg, 8 mg, or 12 mg subcutaneous once weekly, or placebo, using a dose-escalation titration protocol.
Least-squares mean percent body weight change at 48 weeks: -8.7% (1 mg), -17.1% (4 mg), -22.8% (8 mg), -24.2% (12 mg), -2.1% placebo. At 24 weeks the 12 mg group had already achieved -17.5% versus -1.6% placebo. All active arms were statistically significant versus placebo [1].
Approximately 26% of participants in the Phase 2 obesity trial achieved 30% or greater weight loss [16]. No severe hypoglycemia was reported across any active arm.
Phase 2 Type 2 Diabetes Trial: Rosenstock 2023 (Lancet)
The Phase 2 T2D trial (NCT04867785; Rosenstock J et al., Lancet 2023) enrolled 281 adults with type 2 diabetes (HbA1c 7–10.5%, BMI 25–50) and compared retatrutide 0.5, 4, 8, and 12 mg once weekly against placebo and dulaglutide 1.5 mg as an active control.
HbA1c reduction at 36 weeks: -2.02% (12 mg) versus negligible change with placebo. 82% of participants in the 12 mg arm reached HbA1c at or below 6.5% [2]. Body weight: -16.94% (12 mg) versus -3.0% placebo and approximately -3.5% dulaglutide. Retatrutide significantly outperformed the dulaglutide active control on both primary endpoints.
MASLD Liver Fat Trial: Sanyal 2024 (Nature Medicine)
A Phase 2a sub-study (Sanyal AJ et al., Nature Medicine 2024) enrolled 98 adults with MASLD (10% or greater liver fat by MRI-PDFF) from the NCT04881760 Phase 2 obesity cohort.
Mean relative liver fat change (MRI-PDFF) at 24 weeks: -42.9% (1 mg), -57.0% (4 mg), -81.4% (8 mg), -82.4% (12 mg), +0.3% placebo — all active arms statistically significant (P<0.001 vs placebo) [3]. By 48 weeks, 86% of the 12 mg group achieved normal liver fat (below 5%); 93% of the 8 mg group also reached this threshold.
These data establish retatrutide as one of the most effective interventions for hepatic steatosis yet studied in a randomized Phase 2 setting, preceding dedicated Phase 3 MASLD trials.
Visceral Fat Reduction in Retatrutide Trials
A DXA body-composition substudy of the Phase 2 T2D trial (Coskun T et al., Lancet Diabetes and Endocrinology 2025) measured fat distribution at 36 weeks [6]. Total fat mass reduction: 4.9% (0.5 mg), 15.2% (4 mg), 26.1% (8 mg), 23.2% (12 mg) versus 4.5% placebo and 2.6% dulaglutide. Android visceral fat fell by up to 31.4% in the 8 mg arm.
The glucagon receptor component of retatrutide is thought to drive preferential visceral and hepatic fat mobilization beyond what GLP-1R agonism alone achieves, via cAMP-mediated lipolysis in visceral adipose depots and hepatic fatty acid oxidation. Lean mass loss proportion was not disproportionate compared to other anti-obesity medications in the Phase 2 T2D substudy [6].
Note: chronic GCGR activation can cause hypoaminoacidemia and muscle catabolism in rodent models at higher doses; dietary protein supplementation protected lean mass at lower doses in preclinical studies [14]. Phase 2 DXA data in humans did not demonstrate disproportionate lean loss.
Phase 3 TRIUMPH Program: What the Topline Results Show
The TRIUMPH (Triple Receptor Agonist Intervention Utilizing Metabolic Pathways in Health) Phase 3 program enrolled more than 5,800 participants across at least four registered trials.
TRIUMPH-1 (NCT05651776): Adults with obesity or overweight without type 2 diabetes. 80-week primary endpoint. Retatrutide 12 mg: 28.3% mean weight reduction (70.3 lbs); 45.3% of participants achieved 30% or greater weight loss; 65.3% achieved BMI below 30. Extended arm (BMI 35 or greater, 104 weeks): 30.3% mean weight reduction (85.0 lbs). 4 mg arm: 19.0% mean weight loss (47.2 lbs) [5]. Discontinuation due to adverse events: 4.1% (4 mg), 6.9% (9 mg), 11.3% (12 mg) versus 4.9% placebo [17].
TRIUMPH-4: Adults with obesity and knee osteoarthritis. 68-week primary endpoint. Retatrutide 12 mg: 28.7% mean body weight reduction; WOMAC pain score reduction of 75.8% (4.5 points); significant improvements in physical function [8].
TRIUMPH-3 (cardiovascular outcomes) is ongoing; no CVOT results have been published as of May 2026.
Retatrutide Results in Phase 2 and Phase 3 Trials
Across the published Phase 2 and Phase 3 record, retatrutide demonstrates consistent dose-dependent weight loss, with effect sizes that exceed published Phase 2/3 data for dual agonists in indirect comparison.
A network meta-analysis of seven GLP-1 receptor agonists and polyagonists (PubMed 2024) found retatrutide 12 mg at -22.10% body weight, waist circumference -17.00 cm — compared to the dual agonist comparator at -16.53% body weight and -13.23 cm waist in indirect comparison [9]. No direct head-to-head randomized trial between retatrutide and tirzepatide has been published; TRIUMPH-5 is planned for that comparison.
A systematic review and meta-analysis of three RCTs (878 patients) reported: weighted mean difference body weight -14.33% (95% CI -18.27 to -10.39, P<0.00001); BMI -5.38 kg/m² (P<0.00001); waist circumference -10.51 cm (P<0.00001); systolic blood pressure -9.88 mmHg (P<0.00001); fasting glucose -23.51 mg/dL (P<0.00001); HbA1c -0.91% (P<0.00001) [7].
A separate meta-analysis of 3 RCTs (640 patients) reported: body weight WMD -10.66 kg (95% CI -17.63 to -3.69); VLDL -22.74%; systolic BP -4.70 mmHg; HbA1c -0.90%; RR for achieving 20% or greater weight loss: 16.61 (95% CI 4.17–66.12) [12].
Retatrutide vs Tirzepatide: Comparing Triple and Dual Agonists
Tirzepatide is a GLP-1/GIP dual agonist; retatrutide adds a third receptor target — GCGR — producing additional energy expenditure through thermogenesis and hepatic fat oxidation beyond what dual agonism achieves.
In the network meta-analysis (PubMed 2024), retatrutide 12 mg reached -22.10% body weight versus -16.53% for the dual agonist comparator at 15 mg in indirect comparison [9]. No direct randomized head-to-head trial has been published as of May 2026; TRIUMPH-5 is planned for that purpose. The indirect comparison should be interpreted with caution — different trial populations, durations, and titration protocols apply.
Mechanistically: tirzepatide activates GLP-1R and GIPR. Retatrutide adds GCGR activation, which drives brown adipose tissue thermogenesis via cAMP/PKA-mediated UCP-1 activation, hepatic fatty acid oxidation, and increased lipolysis [13]. The glucagon pathway is the primary mechanistic explanation for the additional weight loss observed in indirect comparisons.
Tolerance profiles are similar: both compound classes generate GI-dominant adverse events (nausea, vomiting, diarrhea, constipation) during dose escalation. Discontinuation rates in TRIUMPH-1 Phase 3 (11.3% at 12 mg) are broadly consistent with Phase 3 data for comparable agents [5][17].
The retatrutide vs tirzepatide evidence base is indirect only. The trial record documents each compound independently; no blinded comparison exists.
Comparing Retatrutide and Tirzepatide Outcomes
Indirect comparison of published Phase 2 and Phase 3 data suggests retatrutide achieves greater absolute mean percent weight loss at comparable time points. The 2024 network meta-analysis placed retatrutide 12 mg at -22.10% body weight versus -16.53% for the dual agonist at maximum studied dose [9]. A comprehensive triple-agonism review (Goldney et al., Current Cardiovascular Risk Reports, 2025) confirmed the superior weight loss trajectory observed in the retatrutide trial record versus dual agonists and described the upcoming TRIUMPH-5 head-to-head comparator trial [16].
No published head-to-head randomized trial exists as of mid-2026. Mechanistic differences favor retatrutide for thermogenic effect. Tolerability profiles are similar.